Shalina Healthcare Sarl Pharmaceutical Import Profile — Congo Dr (DGFT 2022–2026)

Name: Shalina Healthcare Sarl Pharmaceutical Import Records from India — 5 Products, $1.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Shalina Healthcare Sarl — Pharmaceutical Importer Profile (2026) | 5 Products, $1.9M Trade | TransData Nexus

Shalina Healthcare Sarl

Pharmaceutical Importer · Congo Dr · Antimalarial & Antiparasitic Focus · $1.9M Total Trade · DGFT Verified

Shalina Healthcare Sarl is a pharmaceutical importer based in Congo Dr with a total trade value of $1.9M across 5 products in 3 therapeutic categories. Based on 97 verified import shipments from Indian Customs (DGFT) records, Shalina Healthcare Sarl is the #1 buyer in 1 product including Paracetamol Caffeine. Shalina Healthcare Sarl sources from 2 verified Indian suppliers, with Shalina Laboratories Private Limited accounting for 93.3% of imports.

Shalina Healthcare Sarl — Import Portfolio & Supplier Network

Shalina Healthcare Sarl import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Shalina Healthcare Sarl?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Shalina Laboratories Private Limited	$38.9M	5,542	93.3%
Shalina Healthcare Private Limited	$2.8M	581	6.7%

Shalina Healthcare Sarl sources from 2 verified Indian suppliers across 2,602 distinct formulations. The sourcing is — Shalina Laboratories Private Limited accounts for 93.3% of total imports, indicating a strategic single-source relationship.

What Formulations Does Shalina Healthcare Sarl Import?

Formulation	Value	Ships
Harmless medicines-epiderm cream 15g	$1.5M	46
Harmless medicines-betasol cream 15g	$860.3K	28
H/m - ibucap forte CAPS 10x10c e/f/p (s/r)	$763.1K	29
H/m - epiderm cream 15g f/p (s/r)	$691.8K	39
H/m-epiderm cream 15g f/p	$533.9K	19
H/m - ibucap CAPS 25x10c e/f/p (s/r)	$529.2K	24
H/m-ibucap forte CAPS 10x10c e/f/p	$406.5K	15
Harmless medicines-betasol lotion 30ML	$404.0K	17
Harmless medicines-ibucap forte CAPS	$386.7K	14
Harmless medicine-maladox tablets 3t	$353.3K	10
Harmless medicines-epiderm cream 30g	$337.2K	10
Ketazol cream 15g e/f/p	$329.3K	13
H/m-ibucap CAPS 25x10c e/f/p	$317.4K	10
Harmless medicine : epiderm cream 15g	$303.2K	11
H/m - tanzol tabs 400MG 1t e/f/p (s/r)	$285.4K	39

Shalina Healthcare Sarl imports 2,602 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Pyrimethamine	Antimalarial & Antiparasitic	$839.8K	44	1.8%	5
2	Sulfadoxine	Antimalarial & Antiparasitic	$839.8K	44	1.6%	5
3	Diazepam	CNS & Psychiatric	$124.6K	5	1.7%	8
4	Ibuprofen Paracetamol	Combination Drugs	$67.8K	2	3.5%	3
5	Paracetamol Caffeine	Combination Drugs	$67.8K	2	4.9%	1

Shalina Healthcare Sarl imports 5 pharmaceutical products across 3 categories into Congo Dr totaling $1.9M. The company is the #1 buyer for 1 product: Paracetamol Caffeine.

Shalina Healthcare Sarl — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Shalina Healthcare Sarl is a prominent pharmaceutical importer and distributor based in the Democratic Republic of Congo (DRC). Established in 1981, the company has been operating in Africa for over four decades, with its headquarters in Dubai and offices in several African countries, including the DRC. Shalina Healthcare Sarl plays a pivotal role in the DRC's pharmaceutical distribution network, ensuring the availability of essential medicines across the country.

The company specializes in sourcing high-quality pharmaceutical products from WHO-approved facilities in India and China, focusing on both generic and branded generic medications. Its extensive product portfolio spans various therapeutic areas, including anti-malarials, antibiotics, anti-inflammatories, and nutritional supplements. By leveraging its strong distribution capabilities, Shalina Healthcare Sarl effectively meets the healthcare needs of the DRC's population.

2Distribution Network

Shalina Healthcare Sarl has developed a robust distribution network within the DRC, with 22 distribution points covering major provinces. This extensive network ensures that pharmaceutical products are readily accessible to both urban and rural communities. The company's logistics capabilities are further enhanced by its partnerships with reputable suppliers, such as Shalina Laboratories Private Limited, which has been a primary source of imported goods.

In addition to its domestic operations, Shalina Healthcare Sarl has expanded its presence across Africa, with offices in countries like Nigeria, Zambia, Angola, Ghana, Kenya, and the Central African Republic. This regional footprint allows the company to leverage economies of scale and streamline its supply chain, ensuring efficient distribution of pharmaceutical products throughout the continent.

3Industry Role

In the DRC's pharmaceutical supply chain, Shalina Healthcare Sarl functions primarily as a wholesaler and distributor. The company imports finished pharmaceutical formulations from India and China, focusing on generic and branded generic products. By sourcing from WHO-approved facilities, Shalina Healthcare Sarl ensures the quality and affordability of its product offerings. Its extensive distribution network across the DRC enables the company to effectively supply medicines to various healthcare providers, including hospitals, clinics, and pharmacies.

Shalina Healthcare Sarl's role as a wholesaler and distributor is crucial in addressing the healthcare needs of the DRC's population. By maintaining a diverse product portfolio and a strong distribution network, the company contributes significantly to the accessibility and availability of essential medicines throughout the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Shalina Healthcare Sarl

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Shalina Healthcare Sarl's sourcing strategy exhibits a high degree of concentration, with a significant majority of its imports originating from a single supplier, Shalina Laboratories Private Limited. This supplier accounted for approximately 93.3% of the total import value, amounting to $38.9 million across 5,542 shipments. Such a concentrated sourcing approach can offer benefits like streamlined logistics and potentially favorable pricing.

However, this dependency also introduces risks related to supply chain disruptions, such as production delays or quality control issues. The absence of alternative suppliers may limit Shalina Healthcare Sarl's ability to mitigate these risks effectively. To enhance supply chain resilience, the company might consider diversifying its supplier base and establishing relationships with additional manufacturers.

The shipment data indicates a stable relationship with Shalina Laboratories Private Limited, as evidenced by the consistent volume of imports over the years. Nonetheless, exploring partnerships with other reputable suppliers could provide Shalina Healthcare Sarl with greater flexibility and security in its sourcing strategy.

2Supply Chain Resilience

Shalina Healthcare Sarl's supply chain resilience is closely tied to its reliance on Shalina Laboratories Private Limited as the primary supplier. While this partnership has facilitated efficient sourcing of pharmaceutical products, the lack of backup suppliers poses a potential vulnerability. In the event of disruptions affecting Shalina Laboratories, Shalina Healthcare Sarl may face challenges in maintaining a consistent supply of medicines.

Importing Pharmaceuticals into Congo Dr — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Congo Dr

1Regulatory Authority & Framework

The regulatory authority overseeing pharmaceutical imports in the DRC is the Ministry of Public Health. The key legislation governing pharmaceutical imports includes the Pharmaceutical Law, which outlines the requirements for importing, distributing, and selling pharmaceutical products within the country. This law ensures that imported medicines meet the necessary quality and safety standards before reaching the market.

The marketing authorization pathway for Indian generics involves obtaining approval from the Ministry of Public Health. This process includes submitting detailed documentation on the product's quality, safety, and efficacy, as well as compliance with Good Manufacturing Practice (GMP) standards. Once approved, the product is granted a marketing authorization, allowing it to be legally imported and distributed within the DRC.

2Import Licensing & GMP

Import licensing requirements in the DRC mandate that all pharmaceutical products, including those from India, must be registered with the Ministry of Public Health before importation. This registration process ensures that imported medicines meet the country's quality and safety standards. Additionally, the Ministry requires that manufacturers adhere to Good Manufacturing Practice (GMP) standards, which are recognized internationally, including EU GMP, WHO GMP, and PIC/S certifications.

Shalina Healthcare Sarl — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Shalina Healthcare Sarl's product category focus on antimalarial and antiparasitic medications, combination drugs, and CNS & psychiatric drugs aligns with the prevalent health challenges in the DRC. Malaria remains a significant public health issue in the country, driving the demand for effective antimalarial treatments. The inclusion of combination drugs and CNS & psychiatric medications addresses the growing need for comprehensive healthcare solutions in these therapeutic areas.

The company's strategic focus on these categories enables it to meet critical healthcare needs and strengthen its position in the DRC's pharmaceutical market. By aligning its product offerings with local health priorities, Shalina Healthcare Sarl demonstrates a commitment to improving the well-being of the DRC's population.

2Sourcing Profile

Shalina Healthcare Sarl's sourcing strategy emphasizes the procurement of generic and branded generic drugs from WHO-approved facilities in India and China. This approach ensures access to high-quality, affordable medicines that meet international standards. The company's focus on finished pharmaceutical formulations, rather than raw APIs or bulk drugs, allows for efficient distribution and addresses the immediate healthcare needs of the DRC's population.

India's established pharmaceutical industry, with its adherence to recognized GMP standards, aligns well with Shalina Healthcare Sarl's

Frequently Asked Questions — Shalina Healthcare Sarl

What products does Shalina Healthcare Sarl import from India?

Shalina Healthcare Sarl imports 5 pharmaceutical products across 3 categories. Top imports: Pyrimethamine ($839.8K), Sulfadoxine ($839.8K), Diazepam ($124.6K), Ibuprofen Paracetamol ($67.8K), Paracetamol Caffeine ($67.8K).

Who supplies pharmaceuticals to Shalina Healthcare Sarl from India?

Shalina Healthcare Sarl sources from 2 verified Indian suppliers. The primary supplier is Shalina Laboratories Private Limited (93.3% of imports, $38.9M).

What is Shalina Healthcare Sarl's total pharmaceutical import value?

Shalina Healthcare Sarl's total pharmaceutical import value from India is $1.9M, based on 97 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Shalina Healthcare Sarl focus on?

Shalina Healthcare Sarl imports across 3 categories. The largest: Antimalarial & Antiparasitic (86.6%), Combination Drugs (7.0%), CNS & Psychiatric (6.4%).

Get Full Shalina Healthcare Sarl Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.